Ace Vision Group Announces Initial Close of $29.4 Million Series B Financing Round
BOSTON, April 24, 2025 (GLOBE NEWSWIRE) — Ace Vision Group, Inc, (“AVG” or “the Company”) an emerging medical device company pioneering Laser Scleral Microporation (LSM) therapy for age-related vision loss, today announced the successful close of a $29.4 million Series B financing round.
Explore More Articles
Treatment landscape for presbyopia evolving toward noninvasive options
Noninvasive or minimally invasive approaches may be the solution for presbyopia before the onset of age-related cataract and a way to address the increasing need to perform close-range tasks. “The treatments that are currently available have not met our needs,” OSN Cornea/External Disease Board Member Eric D. Donnenfeld, MD, said. “Glasses are an inconvenience. Contact lenses cause …
read moreAce Vision Group Names Rob Kissling, MD, as Chief Medical Officer
Ace Vision Group announced that it has named Rob Kissling, MD, as Chief Medical Officer. Dr. Kissling has more than 20 years of experience integrating clinical development, medical strategy, and business planning to develop and commercialize devices and medicines for ophthalmology. His tenure has included companies such as Pharmacia, Pfizer, and Novartis. Most recently, he …
read moreLaser scleral microporation may solve biomechanical problem of presbyopia
CHICAGO — In this Healio Video Perspective from Eyecelerator@AAO, Alex Lopez of Ace Vision Group discusses laser scleral microporation for presbyopia. Lopez said the GenII device can potentially deliver improved near vision without compromising distance vision in patients with presbyopia. The company plans to do a study in the United States in 2026, potentially leading to commercial availability in …
read more